XOMA (US) LLC's Development Partner Servier Launches Proof-of-Concept Clinical Program for Gevokizumab

Published: Jun 25, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BERKELEY, Calif., June 25, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that its development partner, SERVIER, has launched its own independent Proof-of-Concept (POC) clinical program to evaluate the safety and efficacy of gevokizumab, a potent modulator of interleukin-1 beta (IL-1 beta). XOMA launched a similar POC clinical program in November 2011, which included studies in three separate indications: moderate to severe inflammatory acne vulgaris, erosive inflammatory osteoarthritis of the hand, and non-anterior scleritis. SERVIER has selected several indications across multiple therapeutic areas.

Help employers find you! Check out all the jobs and post your resume.

Back to news